E
STSA

Ergoteles’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Ergoteles’s Portfolio STSA Stock Details STSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-42,000
Closed -$296K – 1806
2021
Q2 		$296K Buy
+42,000
New +$226K 0.01% 1074

Other funds holding STSA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's STSA Position: Q3 2021 in Review

Ergoteles sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q3 2021, closing a stake of 42,000 shares — an estimated $296K sold.

Ergoteles first reported a position in STSA in Q2 2021 and held it in 1 quarter. The position peaked at $296K in Q2 2021. 45 funds tracked by Wall St. Rank hold STSA as of Q3 2021.

  • Ergoteles reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Ergoteles sold 42,000 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $296K.
  • Ergoteles first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Ergoteles's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $296K in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.